KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Cost of Revenue (2016 - 2025)

Neogenomics (NEO) has disclosed Cost of Revenue for 16 consecutive years, with -$128.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 32.66% year-over-year to -$128.7 million, compared with a TTM value of $92.0 million through Dec 2025, up 658.95%, and an annual FY2025 reading of $92.0 million, up 8.69% over the prior year.
  • Cost of Revenue was -$128.7 million for Q4 2025 at Neogenomics, down from $21.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $153.2 million in Q2 2023 and bottomed at -$191.1 million in Q4 2024.
  • Average Cost of Revenue over 5 years is $24.5 million, with a median of $47.9 million recorded in 2021.
  • The sharpest move saw Cost of Revenue crashed 1198.08% in 2023, then surged 458.28% in 2024.
  • Year by year, Cost of Revenue stood at $15.9 million in 2021, then grew by 7.7% to $17.1 million in 2022, then plummeted by 1198.08% to -$188.2 million in 2023, then fell by 1.51% to -$191.1 million in 2024, then skyrocketed by 32.66% to -$128.7 million in 2025.
  • Business Quant data shows Cost of Revenue for NEO at -$128.7 million in Q4 2025, $21.8 million in Q3 2025, and $104.1 million in Q2 2025.